Thomas brings Wugen over 20 years of experience in biopharma and clinical practice, including research and development, ...

Finkelstein Chair in Biology, professor and chair of the Department of Cancer Biology and Molecular Medicine at Beckman ...

" I’m honored to join Innate Pharma at such a pivotal moment in its evolution,”said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “ We achieved notable regul ...

Sonrai’s AI data management and analysis technology will enable the Henri & Belinda Termeer Center for Targeted Therapies at ...

Michael Platten is the winner of the “Breakthrough of the Year 2024” in the Life Sciences category of the Falling Walls Foundation.

EMA granted clearance to advancebelrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in ...

Global Phase 1 study of CLN-978 in systemic lupus erythematosus (SLE) cleared to initiate in U.S. and Australia; initial clinical data expected ...

Achievement of all anticipated 2024 milestones and accelerated development timelines reinforce progress on OnTarget 2026 operating plan towards first approved product in 2026. Lea ...

The University of Chicago, Center for Translational Data Science is the maintainer organization ... data platforms to support research in topics of societal interest including cancer, cardiovascular ...

Ribbon Bio GmbH, the DNA synthesis company, announced today that John Luckey, Ph.D. has been appointed Chief Technology Officer. Dr. Luckey brings more than 25 years of technology development ...

Testing new substances in animals is a regulatory cornerstone of drug development. At the same time, the development of animal free testing methods is progressing. In this context the pharmaceutical ...